NO20012105D0 - Farmasöytiske preparater for immunologiske sykdommer - Google Patents
Farmasöytiske preparater for immunologiske sykdommerInfo
- Publication number
- NO20012105D0 NO20012105D0 NO20012105A NO20012105A NO20012105D0 NO 20012105 D0 NO20012105 D0 NO 20012105D0 NO 20012105 A NO20012105 A NO 20012105A NO 20012105 A NO20012105 A NO 20012105A NO 20012105 D0 NO20012105 D0 NO 20012105D0
- Authority
- NO
- Norway
- Prior art keywords
- antigen
- jtt
- pharmaceutical preparations
- antibody against
- immunological diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24267299 | 1999-08-30 | ||
| JP2000254680 | 2000-08-24 | ||
| PCT/JP2000/005868 WO2001015732A1 (fr) | 1999-08-30 | 2000-08-30 | Traitements de maladies immunitaires |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20012105D0 true NO20012105D0 (no) | 2001-04-27 |
| NO20012105L NO20012105L (no) | 2001-06-29 |
| NO332264B1 NO332264B1 (no) | 2012-08-13 |
Family
ID=26535864
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012105A NO332264B1 (no) | 1999-08-30 | 2001-04-27 | Anvendelse av et antistoff som binder til AILIM for fremstilling av et medikament for forebyggelse, behandling eller profylakse av "graft versus host"-sykdom (GVHD), og immunrejeksjon som folge av GVHD. |
| NO20083674A NO20083674L (no) | 1999-08-30 | 2008-08-26 | Farmasoytisk preparat for immunologiske sykdommer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083674A NO20083674L (no) | 1999-08-30 | 2008-08-26 | Farmasoytisk preparat for immunologiske sykdommer |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7465445B2 (no) |
| EP (1) | EP1125585B1 (no) |
| JP (1) | JP3871503B2 (no) |
| KR (2) | KR20040028960A (no) |
| CN (2) | CN1359302A (no) |
| AT (1) | ATE517925T1 (no) |
| AU (1) | AU6865000A (no) |
| BR (1) | BR0007047A (no) |
| CA (1) | CA2348954C (no) |
| CZ (1) | CZ304013B6 (no) |
| HK (1) | HK1040489A1 (no) |
| HU (1) | HU228575B1 (no) |
| ID (1) | ID30042A (no) |
| IL (2) | IL142691A0 (no) |
| NO (2) | NO332264B1 (no) |
| NZ (1) | NZ529577A (no) |
| RU (1) | RU2203682C2 (no) |
| SK (1) | SK288074B6 (no) |
| TR (1) | TR200101205T1 (no) |
| WO (1) | WO2001015732A1 (no) |
| ZA (1) | ZA200103314B (no) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
| US7708993B2 (en) | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
| US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
| KR20010101987A (ko) | 1999-02-03 | 2001-11-15 | 스티븐 엠. 오드레 | 면역 반응과 관련된 신규한 폴리펩티드 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| JP3597140B2 (ja) * | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| US7220822B2 (en) * | 2000-11-22 | 2007-05-22 | The Ohio State University | CD28 mimetics for blocking T cell mediated immune reactions |
| JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| WO2008137915A2 (en) * | 2007-05-07 | 2008-11-13 | Medimmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP3147297B1 (en) | 2011-03-31 | 2018-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
| DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
| PT2717887T (pt) | 2011-06-09 | 2018-04-04 | Univ Florida | Métodos para tratamento ou prevenção da doença do enxerto contra hospedeiro |
| US9695247B2 (en) | 2012-09-03 | 2017-07-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies directed against ICOS for treating graft-versus-host disease |
| JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| KR20180132783A (ko) | 2016-04-07 | 2018-12-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조절제로서 유용한 헤테로사이클릭 아미드 |
| KR102527784B1 (ko) | 2016-04-07 | 2023-04-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조정제로서 유용한 헤테로시클릭 아미드 |
| CN109328188A (zh) | 2016-05-05 | 2019-02-12 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Zeste增强子同源物2抑制剂 |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2756236C2 (ru) | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | PD-L1 специфические антитела |
| US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| BR112019002529A2 (pt) | 2016-08-09 | 2019-05-28 | Kymab Ltd | anticorpo isolado, composição, método para modular o equilíbrio de células t, método para tratar uma doença ou afecção tratável com terapia, método para tratar câncer, combinação de anticorpo igg1, anticorpo anti-icos, mamífero não humano transgênico, e método para produzir um anticorpo |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| CA3048174A1 (en) | 2016-12-22 | 2018-06-28 | Daiichi Sankyo Company, Limited | Anti-cd3 antibody and molecules comprising the antibody |
| CA3052767A1 (en) | 2017-02-27 | 2018-08-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| WO2018225034A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| EP3634483A1 (en) | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy |
| JP2020522541A (ja) | 2017-06-09 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| BR112020005028A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento em combinação para câncer |
| EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
| BR112020006780A2 (pt) | 2017-10-05 | 2020-10-06 | Glaxosmithkline Intellectual Property Development Limited | moduladores do estimulador de genes do interferon (sting) |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| US20210260033A1 (en) | 2018-05-31 | 2021-08-26 | Glaxosmithkline Intellectual Property Development Limited | Combined therapy with icos binding proteins and argininemethyltransferase inhibitors |
| WO2019229614A1 (en) | 2018-05-31 | 2019-12-05 | Glaxosmithkline Intellectual Property Development Limited | Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer |
| CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| EP3870219A1 (en) | 2018-10-22 | 2021-09-01 | GlaxoSmithKline Intellectual Property Development Ltd | Dosing |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| CN114729049A (zh) | 2019-09-27 | 2022-07-08 | 葛兰素史密斯克莱知识产权发展有限公司 | 抗原结合蛋白 |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| JP2023521227A (ja) | 2020-04-14 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 癌の併用療法 |
| AU2021256925A1 (en) | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| CN115698075A (zh) | 2020-04-14 | 2023-02-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗 |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
| BR112023017296A2 (pt) | 2021-03-02 | 2023-11-14 | Glaxosmithkline Ip Dev Ltd | Piridinas substituídas como inibidores de dnmt1 |
| EP4314060A1 (en) | 2021-03-31 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| WO2022243378A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| JP3162438B2 (ja) | 1991-09-12 | 2001-04-25 | 住友製薬株式会社 | 高感度特異的抗体測定法 |
| US5484892A (en) * | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5747461A (en) * | 1994-07-26 | 1998-05-05 | Markov; Angel K. | Synergistic administration of cyclosporine and fructose diphosphate |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US5914112A (en) * | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
| DK0877626T3 (da) | 1996-01-23 | 2002-12-30 | Univ Vermont | Anti-CD18 antistoffer til anvendelse mod slagtilfælde |
| AU723669B2 (en) | 1996-09-18 | 2000-08-31 | Zetesis S.P.A | Use of proteins as agents against autoimmune diseases |
| BR9713498A (pt) | 1996-11-08 | 2000-02-29 | Idec Pharma Corp | Identificação de interações de ligação singulares entre alguns anticorpos e os antìgenos co-estimulatórios b7.1 e b7.2 humanos |
| CA2194814A1 (en) * | 1997-01-10 | 1998-07-10 | Terry L. Delovitch | Stimulation of protective t cells to prevent autoimmune disease |
| WO1998037415A1 (en) | 1997-02-20 | 1998-08-27 | The Regents Of The University Of California | ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME |
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| WO2001018022A1 (en) | 1999-09-03 | 2001-03-15 | Human Genome Sciences, Inc. | 52 human secreted proteins |
| AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
| IL132882A0 (en) * | 1997-05-17 | 2001-03-19 | Biogen Inc | Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses particularly graft rejection |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| AU752433B2 (en) | 1997-09-23 | 2002-09-19 | Bundesrepublik Deutschland letzvertreten durch Den Direktor des Robert-Koch-Instituts | Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use |
| JPH11228442A (ja) | 1998-02-09 | 1999-08-24 | Cypros Pharmaceut Corp | 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用 |
| AU767241B2 (en) * | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
| JP2000154151A (ja) | 1998-09-14 | 2000-06-06 | Kyo Jo | 免疫抑制剤 |
| AU1102000A (en) | 1998-10-07 | 2000-04-26 | Millennium Pharmaceuticals, Inc. | Novel th2-specific molecules and uses thereof |
| KR20010101987A (ko) | 1999-02-03 | 2001-11-15 | 스티븐 엠. 오드레 | 면역 반응과 관련된 신규한 폴리펩티드 |
| CN1377279A (zh) | 1999-05-06 | 2002-10-30 | 遗传研究所有限公司 | 可溶性共同刺激分子增强免疫应答的用途 |
| US6613327B1 (en) | 1999-07-28 | 2003-09-02 | Genetics Institute, Inc. | Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal |
| AU6458400A (en) | 1999-08-11 | 2001-03-13 | Isis Innovation Limited | Nucleic acid, polypeptides, assays, therapeutic methods and means |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP4737905B2 (ja) | 1999-09-21 | 2011-08-03 | ジェネティクス インスティテュート，エルエルシー | Ｇｌ５０分子およびその使用 |
| AU1342501A (en) | 1999-10-29 | 2001-05-14 | Human Genome Sciences, Inc. | 32 human secreted proteins |
| AU2001245396A1 (en) | 2000-03-02 | 2001-09-12 | Mayo Foundation For Medical Education And Research | Hb7-h2, a novel co-stimulatory molecule |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| AU2002217969B2 (en) | 2000-11-28 | 2007-12-20 | Amgen Canada Inc. | Polypeptides involved in immune response |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
-
2000
- 2000-08-29 JP JP2000258470A patent/JP3871503B2/ja not_active Expired - Fee Related
- 2000-08-30 KR KR10-2004-7001435A patent/KR20040028960A/ko not_active Application Discontinuation
- 2000-08-30 EP EP00956800A patent/EP1125585B1/en not_active Expired - Lifetime
- 2000-08-30 CN CN00802420A patent/CN1359302A/zh active Pending
- 2000-08-30 CN CN2006101006481A patent/CN101028519B/zh not_active Expired - Fee Related
- 2000-08-30 ID IDW00200101165A patent/ID30042A/id unknown
- 2000-08-30 HU HU0200994A patent/HU228575B1/hu not_active IP Right Cessation
- 2000-08-30 NZ NZ529577A patent/NZ529577A/en not_active IP Right Cessation
- 2000-08-30 RU RU2001114516/14A patent/RU2203682C2/ru not_active IP Right Cessation
- 2000-08-30 SK SK732-2001A patent/SK288074B6/sk not_active IP Right Cessation
- 2000-08-30 KR KR1020017005279A patent/KR100609441B1/ko not_active IP Right Cessation
- 2000-08-30 WO PCT/JP2000/005868 patent/WO2001015732A1/ja active IP Right Grant
- 2000-08-30 CZ CZ20011720A patent/CZ304013B6/cs not_active IP Right Cessation
- 2000-08-30 AU AU68650/00A patent/AU6865000A/en not_active Abandoned
- 2000-08-30 BR BR0007047-5A patent/BR0007047A/pt active Search and Examination
- 2000-08-30 AT AT00956800T patent/ATE517925T1/de not_active IP Right Cessation
- 2000-08-30 CA CA2348954A patent/CA2348954C/en not_active Expired - Fee Related
- 2000-08-30 TR TR2001/01205T patent/TR200101205T1/xx unknown
- 2000-08-30 IL IL14269100A patent/IL142691A0/xx unknown
-
2001
- 2001-04-19 IL IL142691A patent/IL142691A/en not_active IP Right Cessation
- 2001-04-24 ZA ZA200103314A patent/ZA200103314B/en unknown
- 2001-04-27 NO NO20012105A patent/NO332264B1/no not_active IP Right Cessation
-
2002
- 2002-02-22 HK HK02101307.4A patent/HK1040489A1/zh unknown
-
2003
- 2003-12-05 US US10/729,880 patent/US7465445B2/en not_active Expired - Fee Related
-
2008
- 2008-08-26 NO NO20083674A patent/NO20083674L/no not_active Application Discontinuation
- 2008-11-11 US US12/268,832 patent/US7998478B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20012105D0 (no) | Farmasöytiske preparater for immunologiske sykdommer | |
| Mestecky et al. | Intestinal IgA: novel views on its function in the defence of the largest mucosal surface | |
| Yoo et al. | Induction of arthritis in monkeys by immunization with type II collagen. | |
| PT857068E (pt) | Imunoterapia do cancro e doencas infecciosas utilizando celulas que apresentam antigenios sensibilizadas com complexos de proteina de choque termico-antigenio | |
| DE69230545D1 (de) | Antikörperderivate | |
| ZAWADZKI et al. | Rheumatoid arthritis terminating in heavy-chain disease | |
| DE69030172T2 (de) | Impfstoffe gegen Krebs und Infektionskrankheiten | |
| FI830897L (fi) | Foerfarande foer framstaellning av nya konjugat, vari enzym och antikropp aer bundna vid varandra medelst en kovalent bindning | |
| DK0742795T3 (da) | Immunstimulerende monoklonale antistoffer | |
| FI852683A0 (fi) | Immunisk motverkan foer tumoerer och virus. | |
| Shigesue et al. | Effects of maitake (Grifola frondosa) polysaccharide on collagen-induced arthritis in mice | |
| BE888906A (fr) | Procede de preparation d'un antigene et d'un anticorps du glucagon intestinal | |
| NO922622L (no) | Biomasse for fremstilling av virus/virusantigen | |
| ES2054115T3 (es) | Fenilhidrazonas, su fabricacion y medicamentos y productos cosmeticos fabricados a partir de estas. | |
| Suszko et al. | Effects of polysaccharide fractions isolated from Caltha palustris L. on the activity of phagocytic cells & humoral immune response in mice with collagen-induced arthritis: A comparison with methotrexate | |
| Klein et al. | Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract | |
| NORMIER et al. | NK‐cell stimulating properties of a membrane proteoglycane from non‐capsulated Klebsiella pneumoniae biotype a | |
| Kanoh et al. | (3) Clinicopathological Features and Etiopathogeneses of Defective Defense Mechanisms in Primary Immunodeficiency Diseases | |
| JPS54119019A (en) | Prophylactic and remedy for infectious diseases of young pig, and method for administration thereof | |
| WHITTINGHAM et al. | DINA SERGIESCU, ITALINA CERUTrI, ALICE KAHAN, DOMINIQUE PIATTER & ELLY EFTHYMIOU: Isoprinosine delays the early appearance of autoimmunity in NZB/NZW F, mice treated with interferon 36 RA HUBBARD, MC AGGIO, BB Lozzio & CJ WUST: Correlation ofcirculating immune complexes and disease status in patients with leukaemia 46 | |
| Gathuru | Immunization of lymphocytes in vitro and monoclonal antibody preparation to tumor-associated glycosphingolipid antigens | |
| Currey | Therapeutic alteration of immune responses in rheumatoid arthritis: is it relevant? | |
| NO905006L (no) | Humane, monoklonale antistoffer med reaktiviter overfor pseudomonas aeruginosa, celler som kan produsere antistoffene, fremgangsmaater for fremstilling derav og farmasoeytiskepreparater derav. | |
| Faulk | Immunological approaches to the study of gut function | |
| MARROW | WP FAULK |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |